is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™.

What are Allosteramers™?

Allosteramers™ are a new class of oral, potent, therapeutic drugs developed using Allostera’s Module X platform technology.

Allosteramers™ are short pieces of the body’s own proteins, called peptides, composed of 8 to 10 D-amino acids, that have exceptional and predictable drug properties such as oral activity, pharmacokinetics (length of time in the blood) and metabolism. Allosteramers™ have an “allosteric mechanism,” that is, they are not competitive with natural inhibitors in the body, and have the potential for better efficacy and better selectivity for their targets than small molecules.

Allosteramers™ have the selectivity of monoclonal antibodies with the oral delivery of small molecules.